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A B S T R A C T
Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the
application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID-
19, as well as detail an intensive immunotherapy intervention hypothesis.
We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTX-
LR) rescue can abolish ‘PANIC’, thereby ‘left-shifting’ severe COVID-19 patients to the group majority of those
infected with SARS-CoV-2, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is en-
dowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely available agent
which can be administered early in the course of severe COVID-19 thus rescuing the critical and irreplaceable
gas-exchange alveoli.
Further, we describe a preventative treatment intervention regimen for those designated as having mild to
moderate COVID-19 disease, but who exhibit features which herald the transition to the severe variant of this
disease. Both of our proposed hypothesis-driven questions should be urgently subjected to rigorous assessment in
the context of randomized controlled trials, in order to confirm or refute the contention that the approaches
characterized herein, are in fact capable of exerting mitigating, if not abolishing, effects upon SARS-CoV-2
triggered ‘PANIC Attack’. Confirmation of our immunotherapy hypothesis would have far-reaching ramifications
for the current pandemic, along with yielding invaluable lessons which could be leveraged to more effectively
prepare for the next challenge to global health.
1. Hypothetical strategies for rescuing the severely affected
COVID-19 patient
We submit that the best chance to rescue those afflicted with the
severe variant of COVID-19 depends upon the decision to intervene
with a corresponding assemblage of diverse immune modulatory
agents, each directed toward a mechanistically distinctive component
of the activated inflammatory network's machinery. Such an in-
creadibly diverse combination of agents would require a synchrony of
action in order to arrest the ‘irrationally exuberant’, poorly coordinated,
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and regulatory-deficient immune network in patients with severe
COVID-19 symptoms.
This prolific activation, and expansive constellation of coin-
cidentally activated inflammatory cascades, confers potentially de-
structive consequences upon host tissue compartments which harbor
SARS-CoV-2 (i.e. bystander damage). In contrast to the application of a
multi-component treatment strategy, the identification of a single agent
endowed with pleiotropic mechanistic properties, and capable of re-
constituting the normally coordinated immune-regulatory response
characteristics to SARS-CoV-2, would represent a potential advance in
our struggle to transition severely affected COVID-19 patients into the
‘mild’ phenotypic variant of this Coronavirus-mediated disorder.
2. Survival of the ‘FOCUSED’
The categorical designation of ‘mild COVID-19’ signifies a con-
siderably more ‘focused’ activation of the immune network compared to
severely affected patients. The majority of mildly infected patients de-
monstrate a short-lived flu-like illness with minimal long-lasting effects
or deficits, furthermore, others have such minimal symptoms as to be
considered to be asymptomatic all together. Clinical manifestations,
along with their magnitude and/or worsening, should give pause to
consider the prospect of acute and directed interventions, which may
potentially serve to mitigate symptoms and reduce the risk of advancing
to a more severe clinical state with an associated worsening prognosis.
Such issues can involve recalcitrant cough, impaired mucus clearance,
perception of a diminished negative inspiratory force of breathing, and
increased risk of nosocomial secondary upper respiratory tract infec-
tions, including, but not limited to MRSA and enteric flora.
Treating a recalcitrant cough may be as simple as offering dex-
tromethorphan, but the addition of quinidine can reduce the former's
metabolism and thereby prolong its action, A dose of 20mg/10mg
respectively is the composition of Nuedexta which is FDA-approved for
pseudobulbar affect, but can be of great utility in the circumstances of
recalcitrant cough.
An expectorant, such as guaifenesin, may aid in mucus clearance,
whereas a bronchodilator may improve perception of a diminished ne-
gative inspiratory force of breathing. Smooth muscle relaxation at the
terminal bronchioles and activation of the beta-2 adrenergic receptor
on lung mononuclear cells may skew the immune milieu from a TH1 to
a TH2 anti-inflammatory phenotype. The intracellular biomarker, sec-
ondary to transmembrane signaling at the beta-2 adrenergic receptor, is
an escalation of cAMP for this effect [1–4].
A bronchodilator in conjunction with inhalational steroids will
likely reduce peripheral airway inflammation. Antibiotics, such as
azithromycin, will mitigate risk of secondary nosocomial upper respiratory
tract infection and act as a protective agent against M. pneumoniae, as well
as other community acquired infection of the airway (but NOT all).
Interventions that help detect worsening, such as home finger pulse
oximetry, may be useful. This multi-faceted interventional approach
may prevent the transformation of the mild phenotype into the severe
disease course and its correspondingly worse prognosis [Vignette 1].
The recovery phase for mildly to moderately affected COVID-19
patients appears to be temporally linked with the emergence of de-
tectable SARS-CoV-2 antibodies; although their relevance to recovery
(i.e. are they endowed with viral-neutralization effects or even pro-
tection in the absence of ‘viral neutralization’ in vitro) and the estab-
lishment of a durable remission is currently a matter of vigorous debate
[5]. Notwithstanding the controversy surrounding the therapeutic re-
levance of SARS-CoV-2 associated antibodies, the donation of plasma
derived from patients dichotomized to the mildly affected cohort, and
administered to more severely affected patients, can exhibit impressive
remission-exacting effects [5–7]. This salient observation, in conjunc-
tion with inadequate evidence to confirm the relevance of SARS-CoV-2
antibodies, makes it is entirely feasible to assume that one, or even a
variety of plasma-derived soluble factors from recovered COVID-19
patients, may serve to promote recovery in severely affected patients.
Those dichotomized into the ‘severe COVID-19’ subgroup, because
of their ‘PANIC Attack’ disease course, fail to organize the coordinated
neutralization of SARS-CoV-2, in contradistinction to mildly to mod-
erately affected patients who do in fact eventually orchestrate effective
clearance of the COVID-19 pathoetiologic agent. Alternately, the se-
verely affected cohort of patients will exhibit evidence of the coincident
activation of both the innate and adaptive limbs of the inflammatory
response network; which is in keeping with our definition of the ‘pro-
lific activation of a network-immune-inflammatory crisis’ (i.e. PANIC),
and provides an attractive explanation for why the most severely af-
fected COVID-19 patients harbor stereotyped patterns of irreversible
tissue destruction, including but not limited to, the obliteration of the
life-sustaining process of gas exchange within the terminals of the
bronchopulmonary tree.
3. Anti-cytokine monoclonal antibody therapy
The observation of the cytokine release syndrome (CRS) appears to
be, at least in part, secondary to the accelerated viral replication
characteristics within the peripheral lung alveolar network, ultimately
culminating in the massive release of newly assembled virions during
cellular apoptosis, a process which also results in the release of pro-
inflammatory mediators. Apoptosis resulting in the exaggerated and
paroxysmal release of inflammatory effector elements is now referred to
as pyroptosis (Preprint: Yang M. Cell pyroptosis, a potential pathogenic
mechanism of 2019-nCoV infection. SSRN Electron J 2020). In fact,
pyroptosis is the process most likely responsible for the pathobiologic
underpinnings of the so-called ‘cytokine storm’ (representing an im-
portant mechanism among a constellation of pathobiological under-
pinnings, which collectively represent the new rubric, which we have
defined as PANIC) which involves the rapid release of a broad re-
pertoire of cytokine and chemokine effector elements including TNF-α,
IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TGFβ; CCL2, CCL3, CCL5, CXCL8,
CXCL19, and CXCL10.
In conjunction with the CRS, the SARS-CoV-2 virus is further able to
provoke what we believe to represent a redistribution of immune ef-
fector cells into the lungs, with the consequent intensification of tissue
damage secondary to such cells releasing their corresponding effector
elements, free radicals and reactive oxygen species, such as super oxide
(O−).
The viral spike glycoprotein which decorates the outside surface of
SARS-CoV-2, and serves as the ligand for ACE-2-r, also happens to re-
present a strongly immunogenic portion of the viral architecture [8].
During the process of viral binding to the alveolar ACE-2-r, in addition
to utlizing the endosomal pathway for cell entry, SARS-CoV-2 can enter
cells via the fusion process. In vitro evidence suggests SARS-CoV-2 can
also facilitate the generation of multinucleated cells [Fig. 3 in Part I],
which are also known as syncytia [9].
Cells infected with SARS-CoV-2 express external spike protein,
which can interact with anti-spike IgG (possibly also IgM) antibodies.
The result is the establishment of antigen-antibody complexes capable
of complement fixation, and ultimately complement-dependent cellular
(alveoli epithelium representing the ‘kill-target’ in this case) cytotoxi-
city [see ‘H' in Fig. 3 of Part I].
The anti-IL-6 monoclonal antibody, tocilizumab, has been shown to
provide a mitigating effect upon the Cytokine Release Syndrome, in
addition to reducing fevers, CRP levels, and improving the chest CT
demonstrated lung abnormalities (e.g. the ground glass opacifications)
in COVID-19 positive patients [10,11].
Tocilizumab is a humanized anti-interleukin-6-receptor (IL-6R)
monoclonal antibody (mAb) that inhibits interleukin-6 (IL-6) signaling.
However, the current understanding of the effects on mortality and
morbidity of tocilizumab are still up for debate [12–20]. Similarly, the
IL-1 receptor antagonist anakinra, may improve the clinical disposition
of septic patients with COVID-19, especially those who harbor evidence
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of the macrophage activation syndrome [21].
4. Biomarkers implicating SARS-CoV-2 triggered ‘PANIC’ attack
A primary aim of this 2-part series has been to advance and sub-
stantiate the hypothesis that the pathobiological underpinnings of se-
verely affected COVID-19 patients are principally related to the ‘PANIC’
Attack. Specifically that such patients mount exaggerated and injurious
inflammatory cascades spanning the broad dynamic range of the ef-
fector mechanisms which endow the human immune network. The
unintended consequences of this process include bystander tissue in-
jury, particularly destruction of the most distal and delicate micro-
anatomy of the bronchopulmonary tree, given the proclivity of the
SARS-CoV-2 spike glycoprotein binding to the robust expression of
ACE2-r on the alveolar epithelium.
The pleiotropic mechanisms of tissue injury involved in severely
affected COVID-19 patients mean that targeting a single regulatory
cytokine (e.g. IL-1 or IL-6) is highly unlikely to adequately uncouple the
confluence of convergent inflammatory cascades that appear to rapidly
descend upon the bronchopulmonary tree, ultimately resulting in an
irreversible and step-wise decrement of the alveolar gas-exchange ap-
paratus.
When a critical corpus of functional alveoli are lost, there is an
accelerated failure to adequately load oxygen sufficient to deliver the
substrate required for aerobic respiration. Virtually every system of the
body requires aerobic respiration in order to maintain the constant
bioenergetic balance between supply and demand of energy substrate
for purposes of homeostasis. The respiration demands of a multiorgan
system that operates across a dynamic range of metabolic circum-
stances with corresponding and rapidly fluctuating energy production
and delivery characteristics must be met or catastrophe ensues.
Our hypothesis is that in the ~20% of SARS-CoV-2 infected patients
with severe COVID-19, activation of innate and adaptive immune cas-
cades working in synchrony inflict a ‘PANIC Attack’ upon the terminal
lung fields. The outcome inevitably involves a hyperacute, and poten-
tially diffuse, malfunction of the incredibly delicate functional interface
between the alveolar epithelium and the single cell thick endothelial
tubes, which comprise the capillaries derived from the pulmonary ar-
teries and those which subsequently become the oxygen-rich blood
vessels which enter into the pulmonary veins. We can ill afford to
permit such a PANIC Attack to proceed without interruption, knowing
that a catastrophic loss of alveoli will ultimately bring the severe
COVID-19 patient to the pathophysiologic threshold beyond which the
lungs will fail to both transfer and load oxygen onto red cell he-
moglobin, and to expel carbon dioxide.
We propose a potentially innovative hypothesis, whereby the ap-
plication of an available, intensive, and highly pleiotropic im-
munotherapy, is characterized by commensurately synchronous and
diametrically opposed actions serving to attenuate the specific sequence
of SARS-CoV-2 triggered PANIC Attack mechanisms. We have employed
this strategy for a number of fulminant and treatment recalcitrant in-
flammatory disorders of the CNS, that upon careful analaysis, suggests
that the immune phenomenonlogy, whether triggered by a foreign
microbe, an adjuvant-enriched vaccine, or the ‘ignition’ of a mon-
umentally severe exacerbation of autoimmunity, all appear to exhibit
common pathobiological mechanisms reminiscent of our definition for
the SARS-CoV-2 triggered PANIC Attack.
Our proposed strategy may serve to abort the uncoordinated and
poorly regulated host immune activities, which appear to be funda-
mentally germane to the development of severe COVID-19, and which
determine its prognostic disposition if the PANIC Attack proceeds with
impunity. Further, we present a vignette [Vignette 1] of a patient with
initially mild COVID-19 disease, who began to exhibit what we sus-
pected were transformational clinical features at high risk for advan-
cing to severe COVID-19, and underscore our multi-modal intervention
strategy for ‘left-shifting’ away from the transition to severe COVID-19.
We follow with a second vignette which underscores the utility of
the application of the HDMTX-LR protocol (the details of which are
provided not only as a supplement at the end of the paper, but also are
detailed in our flow diagram on dichotomizing mild/moderate COVID-
19 from the severe variant, and their respective proposed treatment
interventions). [Flow Diagram].
5. Hypothesis
5.1. Methotrexate & Leucovorin Rescue Will Abolish SARS-CoV-2-Induced
PANIC Attack
5.1.1. A Mechanistically Pleiotropic Rescue Strategy For Severe COVID-19
We suggest that high-dose methotrexate with leucovorin rescue
(HDMTX-LR), an anti-inflammatory and chemotherapeutic agent, is
endowed with impressive mechanistically pleiotropic properties
(Table 1), which are capable of mitigating, if not abolishing, each of the
SARS-CoV-2 triggered mechanisms that compositionally make up the
so-called ‘PANIC Attack’. Further, this array of HDMTX-mediated co-
ordinate actions may provide for the development of active immunity
toward the SARS-CoV-2 infection, reflecting the very real prospect that
such an intervention my serve to ‘left-shift’ the severe COVID-19 patient
to the milder phenotype, along with a correspondingly improved
prognosis. Our prior experience with the application of this intensive
Table 1
Coupling discrete mechanisms of PANIC with correspondingly matched miti-
gating therapeutic properties of high-dose Methotrexate.
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treatment strategy, and the nearly stereotyped remission in our pa-
tients, who, upon presentation, were codified as harboring treatment
refractory syndromes of fulminant inflammatory disorders of CNS (e.g.
multiple sclerosis (MS), neuromyelitis optica spectrum disorder
(NMOSD), Sjogren's associated myelitis, post-vaccinal (dTap) en-
cephalomyelitis, and a series of cases of monumentally severe post-viral
encephalomyelitides). (See Flow chart.)
5.1.2. A Novel, Host-Mediated Syndrome of Deleterious Immune Network
Activation: PANIC
The observation of reminiscent ‘PANIC Attack’ mechanisms across
our expanding set of fulminant inflammatory syndromes appears to be
indistinguishable whether afflicting the CNS or the bronchopulmonary
tree. These salient similarities have prompted us to extrapolate from
our experience with treatment resistant, recalcitrant, and monumen-
tally fulminant immune activation affecting our patients with MS,
NMOSD, Sjogren's syndrome, and in a host of other circumstances
where such catastrophic immune-mediated inflammation, can, if not
identified and treated accordingly, obliterate the triggering agent's
target tissue(s).
We have since utilized the same protocol in many patients, who we
now believe in retrospect were suffering from a form of ‘PANIC’ Attack,
except targeting the central nervous system. In Part I of this two-part
publication, we reported a patient suffering from a severe adenovirus-
Flow chart. Diagnostically Dichotomizing COVID-19 into mild/mod and severe variants along with corresponding treatment interventions, including the protocol
for the application of intensive treatment intervention for the latter with high-dose MTX with Leucovorin rescue. The dotted line around this protocol allows the
reader to ‘cut-out’ this section for easy access and lamination to be carried in the wallet, or posted for clinical staff to access when needed.
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triggered PANIC Attack, characterized by cytokine storm, and an en-
cephalomyelitis, with a PRESS-like pattern distribution of lesions [[44]
in PART I]. His protracted and treatment-recalcitrant course had come
to the point where a decision was made to consider cessation of care.
However, it was finally agreed to try the HDMTX-LR regimen, which
ultimately led to the complete recovery of the patient and resolution of
all of the brain lesions which characterized his syndrome [Fig. 1 in Part
I].
A more recent example considers the plight of a young accountant,
who developed optic neuritis in August of 2017, approximately two
weeks following a dTap vaccine and during the 3rd trimester of her first
pregnancy. Declining steroids, for fear of early term delivery, she re-
covered in a self-limited fashion. However, by October she presented
again, this time with optic neuritis in the fellow eye, in addition to some
sensory and motor manifestations. Investigations revealed an elevated,
blood-derived anti-myelin oligodendrocyte glycoprotein (anti-MOG)
antibody at a titer of 1:1000, and consistent with a post-vaccinal, anti-
MOG associated encephalomyelitis. Treated with corticosteroids, she
failed to improve.
By December, our patient presented again with confusion, psycho-
motor slowing, and MRI demonstrating extensive and severe in-
flammatory lesions throughout much of the cerebral white matter.
Coticosteroids once again were without effect, whereas the application
of our HDMTX-LR protocol was tolerated without any adverse effects.
This therapy rapidly attenuated the disease process, including nor-
malization of her clinical manifestations, in conjunction with a re-
markable disappearance of many of her white matter lesions [Fig. 2 of
Part I]. A few months later, the appearance of new enhancing cerebral
white matter leions prompted us to advance our regimen to a full course
of plasma exchange (5-full volume exchanges; which took 8 days),
followed by another course of HDMTX-LR. From the end of that course
of therapy in early 2018 to the writing of this manuscript, there has
been no recurrence, clinically or radiographically. In fact, most of the
lesional burden has disappeared [Fig. 2 of Part I].
5.2. Calming ‘PANIC’ in Severely affected COVID-19 Patients
5.2.1. A Pleiotropic Immune Stabilization Strategy for SARS-CoV-2 Induced
‘PANIC’ Attack
The application of HDMTX for neoplastic and fulminant in-
flammatory syndromes of the CNS represents a critically important
observation because, despite a steady-state blood to CSF ratio of MTX of
about 30:1 [22], doses of 500mg/m2 or more are necessary to achieve
CNS concentrations of MTX to be sufficiently efficacious against such
disorders. The ability to escalate dosing of MTX while rescuing per-
ipheral folate with leucovorin (folinic acid) represents a unique aspect
of using this agent across a number of disease states.
5.2.2. Pleiotropic Mechanisms of Action for HDMTX
Methotrexate (4-amino-10-methyl folic acid) is both an analog as
well as an antagonist of folic acid, but is capable of exerting its action
via a wide spectrum of pleiotropic mechanisms, such that, it is con-
sidered by the WHO as an essential medicine [22,23] (Fig. 1; Table 1).
5.2.3. Cell Cycle S-Phase Inhibition via Folate-Dependent Enzyme Inhibition
Cells that are rapidly dividing, such as those associated with ma-
lignancy, autoimmunity, and during our proposed PANIC syndrome
associated with SARS-CoV-2 infection, spend an increased time in the
cell cycle synthesis (S) phase. However, MTX, in part, functions as an S
phase inhibitor by depriving nucleoside precursors for both DNA and
RNA synthesis and replication [24].
5.2.4. DNA and RNA Base Synthesis Inhibition
MTX accomplishes this via its potent inhibition of folate-dependent
enzymes for both purine and pyrimidine base synthesis, with particular
implications for the reproduction of Coronavirus virions [Fig. 1]. The
vast majority of such rapidly dividing cells, and viral replication as with
SARS-CoV-2, can manufacture base synthesis only by the de novo (i.e.
from ‘scratch') pathways involving inosine monophosphate dehy-
drogenase (IMDH) for purine, and dihydroorotate dehydrogenase
(DHOD) for pyrimidine biosynthesis. Alternately, the vast majority of
body cells can produce bases by either the de novo or via the salvage
pathways, the latter characterized by the use of partially assembled or
partially broken down bases [24].
Following its entry into the cellular cytoplasm, MTX is poly-
glutamated, which serves to both trap the drug within the intracellular
compartment precluding its ability to efflux, and allow the drug to exert
one of its principal actions: the inhibition of dihydrofolate reductase
(DHFR), as well as other folate-dependent enzymes, such as thymidy-
late synthase, 5-amino-imidazole-4 carboxamide ribonucleotide
(AICAR) transformylase (ATIC), and methylene tetrahydrofolate re-
ductase (MTHFR) [[44] in PART I].
Interestingly, folate supplementation does not abolish either the
anti-inflammatory, the chemotherapeutic actions, or the efficacy of
MTX. This suggests that other mechanisms, independent of folate an-
tagonism, must figure prominently in the potent actions of MTX. For
instance, MTX administration provokes the release of adenosine, a po-
tent anti-inflammatory agent that exerts regulatory effects upon neu-
trophils, macrophages, and T cells [24].
5.2.5. Adenosine Mediated Anti-Inflammatory Mechanisms
Adenosine promotes its action through interaction with its receptors
ADORA2A and ADORA3, where transmembrane signaling activities
result in a reduction of production and release of pro-inflammatory
cytokines such as IL-1β, TNFα, IL-6, and a reduction in the production
of matrix metalloproteinases (MMPs) (the transcription of each requires
NF-κB), as well as an increase in production of tissue inhibitors of
metalloproteinases (TIMPS). An additional action of MTX is the in-
hibition of NFκB. Methotrexate inhibits catabolism of adenosine and
AMP, while increasing release of both ATP and ADP from inflammatory
cells; an effect which modulates the bioenergetic activity, such that
inflammatory cells are diminished in their ability to foment unchecked
pro-inflammatory effector mechanisms [25,26].
5.2.6. JAK/STAT Signaling Platform Suppression
A significant pathway responsible for the transduction of multiple
pro-inflammatory cytokines is the JAK/STAT signaling platform, which
is potently suppressed by mechanisms independent of the folate in-
hibition effects of MTX, as such effects are not reversed by adminis-
tration of folinic acid [Fig. 1B] [27].
5.2.7. Methotrexate Modulation of Reactive Oxygen Species
Methotrexate, through its modulation of reactive oxygen species
(ROS), can induce T cell apoptosis, thereby reducing cytokine produc-
tion and elaboration; with a prominent effect upon the reduction of IL-6
[28–31]. Further, MTX activates JNK, thereby activating downstream
targets such as c-JUN and cFOS, constitutive elements of the AP-1
complex involved in the heightened expression of pro-apoptotic genes,
which increase the propensity to apoptosis [Fig. 1].
5.2.8. Methotrexate Inhibits HMGB1 Binding to RAGE
The high-mobility group box chromosomal protein 1 (HMGB1) is
elaborated by activation or injured immune cells, including monocytes,
macrophages, and dendritic cells, and mediates inflammation [Fig. 1C].
One such example is called ‘alarmin’, which promotes acute in-
flammation followed by tissue repair [32–34]. The effects of HMGB1 is
through its counterreceptor, a receptor for advanced glycan end pro-
ducts (RAGE), and is associated with cell maturation and migration to
the site of injury, whereby chronic inflammation is perpetuated
[35,36]. Methotrexate can inhibit HMGB1 by directly binding to RAGE
or indirectly by inhibition of cytokine production of TNFα, IL-1, IL-6,
IL-8.
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5.2.9. Treatment Protocol for the Application of High-Dose MTX with
Leucovorin Rescue
The proposed HDMTX-LR protocol has been the focus of prior in-
vestigation, the details of which have been published [Table and Fig. 1,
Protocol, & Flow Diagram] [37]. Briefly, prior to therapy we ensure
that the urine specific gravity is< 1.1010, urinalysis and urine culture
are without evidence of infection, the serum creatinine (Scr) is below
1.4 mg/dl. Furthermore, complete blood count (CBC), and the
comprehensive metabolic panel (CMP) to include liver functions and
electrolytes, are assessed prior to administration of HDMTX-LR. For
purposes of reducing the risk of MTX crystalline deposition in the
kidneys, D5W and sodium bicarbonate 100mEq are administered in-
travenously at a rate of 150ml/m2/h for at least 8 h prior to the ad-
ministration of the HDMTX-LR protocol in order to achieve a urine pH
of at least 8.0 before and during the entire HDMTX-LR infusion.
MTX at 2500mg/m2 in 250ml of normal saline is administered
(caption on next page)
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intravenously over 2 h. Precisely 12 h after the inception of the MTX
infusion, we begin leucovorin (folinic acid) rescue with 80mg given
intravenously. Thereafter, leucovorin at 35mg is administered in-
travenously precisely every 6 h for a total of 12 doses [Fig. 1 & Pro-
tocol]. Serum MTX concentration levels are assessed at 24 h, 36 h, 48 h,
and 72 h after the administration of HDMTX-LR. Patient discharge
cannot proceed until the MTX concentration falls below 0.05μmolar
(typically requiring a period of 24–72 h).
Nausea and vomiting tend to occur during or shortly after the
HDMTX-LR administration, hence anti-emetics (e.g. odansetron) are
given 30min before the infusion and as needed thereafter.
Dextromethorphan (5-10mg po prn every 2–4 h; or 20mg with 10mg
of quinidine; Nuedexta daily) is utilized to treat infusion-related
headaches. CBC, Scr, and CMP are assessed at baseline and then at
weeks 1 and 4 following treatment with HDMTX-LR.
Penicillin derivatives, probenecid, fluoroquinolones, sulfonamides,
aspirin, and non-steroidal anti-inflammatory drugs are known to de-
crease renal excretion of MTX and are therefore avoided during
HDMTX-LR treatment. Vancomycin and trimethoprim/sulfamethox-
azole are avoided immediately prior to, and during HDMTX-LR ad-
ministration to avoid potential additive or synergistic nephrotoxicity,
and possible myelosuppression [22].
A range of potential toxicities can be associated with the HDMTX-LR
protocol, each of which, however, can be markedly mitigated, if not
prevented or abolished, with careful attention to the precise proscrip-
tions of our protocol, and the use of systematic and sequential stepwise
transitions to each phase of the therapeutic plan [Protocol]. Most im-
portant is that the HDMTX-LR protocol can be safely employed, while
reducing risk of toxicity by ensuring vigorous hydration (to avoid MTX
crystalline deposition), urine alkalinization (crystal formation is more
likely in acid pH of the genitourinary system), along with the precisely-
timed administration of the leucovorin rescue (to prevent mucositis).
The addition of benfotiamine has been shown to reduce MTX
mediated liver toxicity in those utilizing low dose weekly chronic
dosing of the medication, and the addition of this agent to the high dose
punctuated administration of MTX may also confer some tangible
benefits, albeit a subject for further investigation. Further, adequate
levels of vitamin D (to achieve 60-100 ng/ml) are known to exert im-
munomodulatory effects [38].
5.2.10. Management of Severe COVID-19:Practice Principles
The principal thrust of this paper is to emphasize that the SARS-
CoV-2 induced severe variant of COVID-19 is not mediated by a single
renegade cytokine or immunological phenomenon (e.g. the cytokine
storm). Severe COVID-19 is principally recognized by the requirement
for respiratory support, culminating in pressure ventilation, at which
point the prognosis is poor, with most secumbing to the disease via the
paroxysmal cessation of gas exchange, and the pathophysiologic sig-
nature of irreversible demise, treatment refractory hypoxic-ischemia. At
this point, further interventions become an unnecessary and psycho-
logically devastating exercise in futility for the patient, their family, and
for the front-line care team.
Herein we have underscored the serious nature of COVID-19, the
manifestations and clinical and paraclinical factors which portend this
ominous, and commonly irreversible, semiology. Further, we have
dissected the manifold mechanisms, triggered by SARS-CoV-2. Mild to
moderate COVID-19 is largely defined by the nature, magnitude, loca-
tion, and whether such immune network responses are mechanistically
coherent, and effective, while at the same time being sufficiently ‘fo-
calized’. Focalized responses signify a coordinately-regulated network
immune response, one most capable of limiting the severity of end-
organ tissue damage.
The primary goal of this communication is to help our front line
workers recognize that despite the ‘prolific activation of a network-
mediated inflammatory crisis’, or PANIC Attack, we do in fact have
compositional immunotherapies, that when combined, may serve to
abort or at least mitigate, suffering while promoting an improved
prognosis. Alternately, we herein hypothesize that a single agent en-
dowed with a plethora of diverse and site selective targeting cap-
abilities, each of which is sufficiently robust so as to uncouple the SARS-
Co-V-2 induced PANIC Attack, may be used to lead the counter-attack.
It is precisely for this reason that the WHO has long considered MTX as
a ‘necessary’ medicine.
5.2.11. Future Directions ‘Available Now’
Remdesivir, a newly-approved antiviral therapy for COVID-19, is an
IV formulation that could easily be given simultaneously with HDMTX-
LR by the following rationale: Remdesivir is a nucleotide analog with
broad-spectrum antiviral activity, formulated with a large amount (60:1
weight ratio excess) of the excipient sulfobutylether beta-cyclodextrin
(SBECD, Captisol, Ligand Pharmaceuticals, Inc).
Fig. 1. Methotrexate has been recognized by the World Health Organization as an ‘essential medication’, principally due to its broad diversity of mechanisms of
action. Methotrexate can be utilized at low doses to take advantage of its dynamic range of anti-inflammatory mechanisms (particularly beneficial in the management
of rheumatoid arthritis), or at high doses to eradicate a range of malignancies, or in circumstances of fulminant inflammatory conditions where conventional
approaches have been futile. In this figure we emphasize the pleiotropic and discretely targeted actions of high-dose methotrexate, as a hypothetical intervention for
SARS-CoV-2 triggered PANIC Attack. The viral infection produces a severe variant of COVID-19 following the simultaneous activation of the diverse limbs of the
human immune network (Fig. 1). As such, productive therapeutic strategies are likely combinations of different agents targetting distinctly different mechanisms of
immune activation, or monotherapies endowed with a diversity of actions capable of counteracting the PANIC Attack triggered by SARS-CoV-2. In A) we showcase
methotrexate as a potent inhibitor of the folate-dependent enzyme systems, especially those which are essential in rapidly dividing cells; such as those of the hyper-
activated immune system, given that the cell cycle synthesis (S) phase requires nucleoside precursors for the synthesis of both DNA and RNA by the de novo
pathways; and as such for RNA replication of the SARS-CoV-2 agent. Other body cells overcome this base synthesis blockade by utilizing the so-called salvage
pathways, where partially assembled and partially broken down bases can be utilized to complete the synthesis; which are not available to rapidly dividing cells and
microbes such as SARS-CoV-2. MTX is polyglutamated following entry into cells, a molecular modification which serves to prevent its efflux back out of the cell. Once
inside the cell, this form of the molecule effectively inhibits dihydrofolate reductase among other folate dependent enzyme systems, which ultimately inhibits the de
novo biosynthetic pathways for purines and pyrimidines (necessary for both DNA and RNA); and as such it reduces RNA replication of the virus. In B) we illustrate the
inhibitory effects of MTX on multiple transmembrane signaling pathways involved in inflammation, including the JAK-STAT pathways that are activated by a host of
inflammatory cytokines such as IL-2, IL-6, IL-12, IL-15, GM-CSF, and IFNγ. We also illustrate the role of the NFκB signaling pathway for a series of inflammatory
mediators such as IL-1β, IL-6, TNFα, and for matrix matalloproteases. MTX inhibits the production of these inflammatory mediators, but also liberates reactive
oxygen species (ROS) that then trigger JNK activation, which promotes p53 activity that inhibits NFκB (thereby blocking the effector functions of proinflammatory
cytokines). Further JNK activation also activates the c-Fos and c-Fun pathways that culminate in pro-apoptotic gene expression and increased sensitivity to apoptosis.
In C) we illustrate the ability of MTX to block HMGB1 binding to RAGE receptor, and thereby aborting the multiple downstream immune effector injury mechanisms
that converge to destroy the lung alveoli in severe COVID-19. The attenuation of immune cell maturation, migration and transmigration across the alveoli epithelia
(utilizing matrix metalloproteinases which digest fibronectin, collagen, and other matrix elements that constitute the integrity of tissue elements), and the release of
cytokines and other inflammatory mediators by either active release mechanisms, or via their passive release secondary to the expulsion from damaged or dying cells
are additional alveolar injury pathways that are blocked by MTX. In D) we emphasize a series of risk mitigation interventions that are crucial when using HDMTX-LR
(all of which are further discussed in the text).
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Captisol has been shown to prevent the nephrotoxicity of iodinated
contrast [39]. Its nephroprotective effect includes the inhibition of
apoptosis, in renal tubular cells, induced by numerous nephrotoxins. In
addition, various cyclodextrins have been shown to reduce inflamma-
tion in other models [40–42]. It is conceivable that Captisol may act not
only as a solubilizer for the antiviral agent, but may itself contribute to
the efficacy of remdesivir in the treatment of COVID-19. Thus, re-
mdesivir given with HDMTX-LR may provide synergism in the treat-
ment of PANIC in COVID-19, while at the same time providing ne-
phroprotection for methotrexate.
6. CONCLUSIONS: TIME IS TISSUE
About 20% of COVID-19 patients will ultimately advance to severe
disease, with assimilation of the corresponding risk escalation of both
morbidity and mortality. Most COVID-19 patients shall cycle through a
number of clinical dispositions, each of which may be remediable, and
potentially even mitigated with respect to ‘left-shifting’ the patient and
their course, further away from those thresholds beyond which survival
becomes increasingly more remote. To illustrate, we have prepared two
scenarios as ‘call out boxes’ which contain an abbreviated vignette,
followed by our specific plans of intervention [Box 1 and 2]. The goals
for each scenario are to mitigate suffering, promote reconstitution of
network immune coordinate regulation sufficient to prevent PANIC, but
also to recognize and urgently treat PANIC when the features that de-
fine it are recognized by our front-line workers.
As a synopsis, the mildly affected COVID-19 patient is offered site-
selected delivery of inhalational steroids followed by L-albuterol (R
form of this agent, making it relatively lung selective). This promotes
bronchial smooth muscle relaxation, as well as activates the beta-2
adrenergic receptor on immune cells, thereby rendering them dimin-
ished in their inflammatory activity via activation and escalation of
intracellular cyclic AMP (essentially biasing immune cells from a TH1
to TH2 anti-inflammatory phenotype). Further, low-dose weekly MTX
(7.5 to 25mg taken po weekly along with 2mg of folate daily) could be
utilized in those patients with mild to moderate COVID-19, but who
persist or exhibit what appears to represent a more protracted and
slowly advancing clinical deterioration.
When compared to our HDMTX-LR intervention, low dose weekly






Disease Modifying Therapy Change
1. The patient was lymphopenic on dimethyl fumarate (a recognized association) and with suspected COVID-19. The
significant lymphopenia places this patient at risk for PML, although the lymphopenia can also be secondary to
COVID-19.
2. A decision was made to discontinue the dimethyl fumarate, and to instead begin treatment with interferon beta 1a,
taken SQ every two weeks (Plegridy). Further, given that the patient exhibited breakthrough on interferon in the
past, it was also decided to treat concomitantly with teriflunomide; starting at 7 mg po daily for two weeks; then
escalating to 14mg daily thereafter.
3. Type I interferons exert anti-viral actions, and teriflunomide is an inhibitor of pyrimidine base synthesis, via the
inhibition of the de novo biosynthetic enzyme, dihydroorotate dehydrogenase. Rapidly dividing cells and microbes
such as the SARS-CoV-2 agent must utilize the de novo pathway for DNA and RNA base synthesis, whereas other
body cells can use either de novo or salvage pathways (using partially assembled or partially broaken down bases for
DNA and RNA synthesis).
Shortness of breath 1. Assess oxygen saturation with simple home finger pulse oximetry. Given parameters, patients can provide their
managing physicians with crucial information as to whether the COVID-19 clinical course is deteriorating, and hence
the need for hospitalization.
2. Supplemental Oxygen via nasal canula
Shortness of Breath (Chest Tightness) 1. Postural Percussion performed by husband to facilitate pulmonary hygiene (formerly pulmonary toilet to mobilize
and promote mucus clearance)
2. Incentive Spirometry for deep breathing and exercise of respiratory muscles
Cough:Non-Productive Dextromethorphan
Dextromethorphan (DM)+Quinidine; Nuedexta; (the latter reduces the metabolism of DM). Quinidine is a derivative of
quinine, from the Peruvian Cinchona tree, as are chloroquine and hydroxychloroquine; all of which have been observed





D) Deep terminal airway inflammation
A) Guaifenesin bid for mucus liquification
B) Consider Warm Steam Vaporizer
C) Pulmicort Inhalational steroid
D) Site-selective delivery of anti-inflammatory action into the terminal bronchopulmonary tree
Reactive Airway
1. Bronchial constriction
2. Beta-2 adrenergic receptor mediated immune
skewing
1. Levalbuterol; also known as L-albuterol (Xopenex) and is the active form of the drug called R-albuterol. Fewer side
effects than with racemic albuterol (which is a 50:50 mixture of R and S forms). Pharmacologically acts via the beta-2
adrenergic receptor on bronchial smooth muscle thereby relaxing the distal extent of the bronchopulmonary tree.
Can reduce the ‘tight lung’ perception, and via bronchodilation can facilitate mobilization of mucus and avoid
inspisated mucus organization. Two puffs TID.
2. Beta-2 adrenergic receptors are also expressed on circulating mononuclear cells. R albuterol binds to the beta-2
receptor and promotes conversion of cells of the TH1 proinflammatory phenotype to TH2 anti-inflammatory state
[68–71]. Two puffs TID.
Elevated Blood Pressure Blood pressure monitoring and correlate with headache.
1. Bioenergetics
2. Reduce MTX tissue injury
1. Benfotiamine 300mg daily: Improved bioenergetics
2. reduced tissue damage from MTX and other inciting agents [94].
1. Vitamin D: 10, 000 units of D3 daily for promoting
immune modulation/Tregs
Vitamin D may play an immunoregulatory role in COVID-19 patients [95].
Low Dose Weekly MTX (if needed)
Daily Folic Acid
7.5-25mg po q weekly
2mg of Daily Folate
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can, nevertheless, exert a constellation of attenuating influences in re-
sponse to the SARS-CoV-2 triggering of the broad expanse of the host
immune networks.
Pulmonary toilet (now referred to as pulmonary hygiene) can loosen
and expectorate mucus in the distal bronchopulmonary tree, which is
facilitated by the performance of postural percussion of the back and
sides of the thoracic cage. For chronic cough, dextromethorphan +
quinidine may be prescribed, the latter reducing the metabolism of
dextromethorphan while also providing a derivative of quinine from
the cinchona tree. Quinine, like chloroquine and hydroxychloroquine,
has demonstrated interrupted viral synthesis in vitro, as well as the
release of cytokines. Vitamin D3 taken daily, and at a dose commen-
surate to achiving a blood level of 60-100 ng/ml, can promote immune
regulatory networks, and improve energy (reduce fatigue) [43].
Ultimately, rather than targeting individual cytokines and their re-
ceptors, the HDMTX-LR protocol provides a broader spectrum of pro-
tection against the cytokine storm described herein, as well as the other
mechanisms that collectively we now define as a PANIC Attack.
Whether triggered by immune network dysregulation in autoimmune
disorders, or secondary to a foreign microbe capable of triggering
PANIC, the resultant process occurs in a significant proportion of in-
fected individuals. The pathobiological underpinnings which dichot-
omize those destined to experience mild vs severe COVID-19, shall, and
already is, the subject of vigorous debate, and extensive investigations
by the most gifted and talented physicians, scientists, and physician-
scientistis from around the globe. We truly are in this together, and by
working together, we have our best prospects to conquer this pandemic,
while also preparing for the next ‘PANIC’ Attack(s).
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Box 2
Vignette Box 2
Prevention, Mitigation, or Abolishment of the SARS-CoV-2 Triggered PANIC
A 55-year-old University School of Medicine hospital physician intensivist, and unit Director, has been carefully and systematically managing mild, moderate, and severely affected
COVID-19 patients since March 15, 2020. During this time he has consistently utilized PPE consisting of gloves, disposable gown, N95 masks with facial shields, and head and
shoe covers. On April 22, his unit is visited by a senior member of the COVID-19 Federal Safety Task Force, refuses to wear a mask of any type, so that he is certain to ‘express his
abundant respect’ by not covering his face while he offers his congratulations to the unit Director, as the visit was orchestrated to recognize the heroic efforts of this senior
faculty member, in the management of the most severe cases of COVID-19 in the region. The conversation between the two men is at a distance of about 3–4 ft from each other.
In a lapse in judgment the unit Director removes his mask in order to exhibit his respect for the senior task force representative.
Within 24 h, the unit Director has developed a fever of 101.4 F, a dry, non-productive cough, chest discomfort with inspiration, profound fatigue and malaise, increased work of
breathing, myalgias and exercise intolerance. Laboratory assessment reveals elevated D-Dimer, a CRP of 3.75, CK of 1500, lymphopenia (absolute number= 400), ferritin of
700, and an O2 saturation of 88%. Chest CT reveals multilobar ground glass lesions consistent with COVID-19; while the RT-PCR for SARS-CoV-2 is negative. There is a history of
hypertension, currently being treated with Losartin.
Complaint Intervention
Fever Infection Azithromycin
Shortness of breath 1. Assess oxygen saturation (80%)
2. Supplemental Oxygen 4 L via nasal canula
Shortness of Breath
(Chest Tightness)
3. Postural Percussion to facilitate pulmonary hygiene (formerly pulmonary toilet to mobilize and promote mucus
clearance)
4. Incentive Spirometry for deep breathing and exercise of respiratory muscles
Cough:Non-Productive Dextromethorphan
Dextromethorphan (DM)+Quinidine; Nuedexta; (the latter reduces the metabolism of DM). Quinidine is a derivative
of quinine, from the Peruvian Cinchona tree, as are chloroquine and hydroxychloroquine; all of which have been





H) Deep terminal airway inflammation
E) Guaifenesin bid for mucus liquification
F) Consider Warm Steam Vaporizer
G) Pulmicort Inhalational steroid
H) Site-selective delivery of anti-inflammatory action into the terminal bronchopulmonary tree
Reactive Airway
3. Bronchial constriction
4. Beta-2 adrenergic receptor mediated immune
skewing
3. Levalbuterol; also known as L-albuterol (Xopenex) and is the active form of the drug called R-albuterol. Fewer side
effects than with racemic albuterol (which is a 50:50 mixture of R and S form). Pharmacologically acts via the beta-
2 adrenergic receptor on bronchial smooth muscle thereby relaxing the distal extent of the bronchopulmonary tree.
Can reduce the ‘tight lung’ perception, and via bronchodilation can facilitate mobilization of mucus and avoid
inspisated mucus organization. Two puffs TID.
4. Beta-2 adrenergic receptors are also expressed on circulating mononuclear cells. R albuterol binds to the beta-2
receptor and promotes conversion of cells of the TH1 proinflammatory phenotype to TH2 anti-inflammatory state
[Ref; Weiner Harvard]. Two puffs TID.
Elevated Blood Pressure Blood pressure monitoring and correlate with headache.
3. Bioenergetics
4. Reduce MTX tissue injury
3. Benfotiamine 300mg daily: Improved bioenergetics
4. reduced tissue damage from MTX and other inciting agents
2. Vitamin D: 10, 000 units of D3 daily for promoting
immune modulation/Tregs
Prepare for HDMTX-LR Protocol (Consult the Flow
Diagram for detailed instructions)
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